Hereditary Tyrosinemia Type 1 in Jordan: A Retrospective Study

Background. Hereditary tyrosinemia type 1 (HT1) is a recessively inherited inborn error of metabolism affecting the final step of tyrosine catabolism. The accumulation of tyrosine toxic metabolites leads to progressive hepatic, renal, and neurological manifestations. Treatment of HT1 consists of tyr...

Full description

Saved in:
Bibliographic Details
Main Authors: Noor A. Megdadi, Ahmad K. Almigdad, Mo’men O. Alakil, Shahrazad M. Alqiam, Sumaia G. Rababah, Moshera A. Dwiari
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:International Journal of Pediatrics
Online Access:http://dx.doi.org/10.1155/2021/3327277
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832564819347111936
author Noor A. Megdadi
Ahmad K. Almigdad
Mo’men O. Alakil
Shahrazad M. Alqiam
Sumaia G. Rababah
Moshera A. Dwiari
author_facet Noor A. Megdadi
Ahmad K. Almigdad
Mo’men O. Alakil
Shahrazad M. Alqiam
Sumaia G. Rababah
Moshera A. Dwiari
author_sort Noor A. Megdadi
collection DOAJ
description Background. Hereditary tyrosinemia type 1 (HT1) is a recessively inherited inborn error of metabolism affecting the final step of tyrosine catabolism. The accumulation of tyrosine toxic metabolites leads to progressive hepatic, renal, and neurological manifestations. Treatment of HT1 consists of tyrosine-restricted diets and nitisinone. The untreated disease progresses into life-threatening liver failure with an increased risk of hepatocellular carcinoma. Methods. From April 2010 to March 2021, eighteen patients were diagnosed with HT1 in the metabolic department at Queen Rania Al Abdullah Hospital for Children in Jordan. Patients were reviewed retrospectively regarding their clinical features, laboratory data, and sociodemographic history. Results. The mean age of nine boys and nine girls was 6.03 years (SD±3.85). The mean age for symptom onset was 5.61 months (SD±6.02). However, the diagnosis was belated from the onset by 10.50 months (±10.42). Nitisinone treatment was delayed from diagnosis around 12.28 months (SD±25.36). Most of the patients (66.7%) had acute onset of the disease. Two children (11.1%) died due to hepatic complications. Positive family history was identified in 61.1% of patients, and a similar percentage were born to parents with consanguineous marriage. The most common presentation was abdominal pain, vomiting, and fever. Hepatomegaly and abdominal distention were the most common findings. Six patients’ (42.9%) first presentation was rickets. Conclusion. HT1 diagnosis is usually delayed because it is not part of newborn screening and nonfamiliarity with the clinical features of the disease. Therefore, nationwide newborn screening should be expanded to include HT1.
format Article
id doaj-art-4e63eab4ece44578a02943a0ea3fed4b
institution Kabale University
issn 1687-9759
language English
publishDate 2021-01-01
publisher Wiley
record_format Article
series International Journal of Pediatrics
spelling doaj-art-4e63eab4ece44578a02943a0ea3fed4b2025-02-03T01:10:11ZengWileyInternational Journal of Pediatrics1687-97592021-01-01202110.1155/2021/3327277Hereditary Tyrosinemia Type 1 in Jordan: A Retrospective StudyNoor A. Megdadi0Ahmad K. Almigdad1Mo’men O. Alakil2Shahrazad M. Alqiam3Sumaia G. Rababah4Moshera A. Dwiari5Department of PediatricsDepartment of Orthopedic SurgeryDepartment of PediatricsDepartment of PediatricsDepartment of PediatricsDepartment of PediatricsBackground. Hereditary tyrosinemia type 1 (HT1) is a recessively inherited inborn error of metabolism affecting the final step of tyrosine catabolism. The accumulation of tyrosine toxic metabolites leads to progressive hepatic, renal, and neurological manifestations. Treatment of HT1 consists of tyrosine-restricted diets and nitisinone. The untreated disease progresses into life-threatening liver failure with an increased risk of hepatocellular carcinoma. Methods. From April 2010 to March 2021, eighteen patients were diagnosed with HT1 in the metabolic department at Queen Rania Al Abdullah Hospital for Children in Jordan. Patients were reviewed retrospectively regarding their clinical features, laboratory data, and sociodemographic history. Results. The mean age of nine boys and nine girls was 6.03 years (SD±3.85). The mean age for symptom onset was 5.61 months (SD±6.02). However, the diagnosis was belated from the onset by 10.50 months (±10.42). Nitisinone treatment was delayed from diagnosis around 12.28 months (SD±25.36). Most of the patients (66.7%) had acute onset of the disease. Two children (11.1%) died due to hepatic complications. Positive family history was identified in 61.1% of patients, and a similar percentage were born to parents with consanguineous marriage. The most common presentation was abdominal pain, vomiting, and fever. Hepatomegaly and abdominal distention were the most common findings. Six patients’ (42.9%) first presentation was rickets. Conclusion. HT1 diagnosis is usually delayed because it is not part of newborn screening and nonfamiliarity with the clinical features of the disease. Therefore, nationwide newborn screening should be expanded to include HT1.http://dx.doi.org/10.1155/2021/3327277
spellingShingle Noor A. Megdadi
Ahmad K. Almigdad
Mo’men O. Alakil
Shahrazad M. Alqiam
Sumaia G. Rababah
Moshera A. Dwiari
Hereditary Tyrosinemia Type 1 in Jordan: A Retrospective Study
International Journal of Pediatrics
title Hereditary Tyrosinemia Type 1 in Jordan: A Retrospective Study
title_full Hereditary Tyrosinemia Type 1 in Jordan: A Retrospective Study
title_fullStr Hereditary Tyrosinemia Type 1 in Jordan: A Retrospective Study
title_full_unstemmed Hereditary Tyrosinemia Type 1 in Jordan: A Retrospective Study
title_short Hereditary Tyrosinemia Type 1 in Jordan: A Retrospective Study
title_sort hereditary tyrosinemia type 1 in jordan a retrospective study
url http://dx.doi.org/10.1155/2021/3327277
work_keys_str_mv AT nooramegdadi hereditarytyrosinemiatype1injordanaretrospectivestudy
AT ahmadkalmigdad hereditarytyrosinemiatype1injordanaretrospectivestudy
AT momenoalakil hereditarytyrosinemiatype1injordanaretrospectivestudy
AT shahrazadmalqiam hereditarytyrosinemiatype1injordanaretrospectivestudy
AT sumaiagrababah hereditarytyrosinemiatype1injordanaretrospectivestudy
AT mosheraadwiari hereditarytyrosinemiatype1injordanaretrospectivestudy